Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.51M | $6.30M | $5.84M | $11.8M | $15.6M | $24.1M | $45.8M | $65.0M | $86.7M | $103M |
| Revenue growth | — | 14.5% | -7.4% | 101.6% | 32.5% | 54.9% | 89.9% | 41.8% | 33.4% | 19.0% |
| Gross profit | $4.56M | $5.50M | $5.33M | $10.6M | $14.0M | $21.8M | $39.5M | $57.1M | $78.5M | $95.6M |
| Gross margin | 82.9% | 87.2% | 91.3% | 89.7% | 89.6% | 90.4% | 86.1% | 87.9% | 90.6% | 92.7% |
| Operating income | -$272K | $120K | -$502K | -$2.74M | -$5.03M | -$7.38M | -$12.5M | -$4.22M | $1.26M | $7.30M |
| Operating margin | -4.9% | 1.9% | -8.6% | -23.3% | -32.3% | -30.6% | -27.3% | -6.5% | 1.5% | 7.1% |
| Net income | -$416K | $331K | -$601K | -$2.81M | -$4.45M | -$7.92M | -$7.94M | -$4.30M | -$9.66M | -$37.6M |
| Net margin | -7.5% | 5.3% | -10.3% | -23.9% | -28.5% | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% |
| EPS (diluted) | -$0.01 | $0.00 | $0.00 | -$1.32 | -$0.76 | -$1.08 | -$1.00 | -$0.52 | -$1.14 | -$4.36 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $409K | -$140K | $277K | -$2.17M | -$4.03M | -$4.81M | -$5.55M | -$3.25M | -$23.8K | $6.79M |
| Capital expenditures | $3.03K | $43.9K | $8.48K | $183K | $544K | $172K | $147K | $265K | $206K | $4.63M |
| Free cash flow | $406K | -$184K | $269K | -$2.35M | -$4.58M | -$4.99M | -$5.70M | -$3.51M | -$230K | $2.16M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $833K | $463K | $176K | $6.61M | $455K | $18.7M | $8.96M | $5.15M | $15.9M | $16.6M |
| Total assets | $2.17M | $2.22M | $1.71M | $11.1M | $9.83M | $36.4M | $61.0M | $73.9M | $88.1M | $72.9M |
| Total liabilities | $2.59M | $2.12M | $1.12M | $4.72M | $3.99M | $6.24M | $19.3M | $29.3M | $49.2M | $67.0M |
| Long-term debt | — | — | — | — | — | — | — | $9.11M | $30.7M | $46.0M |
| Shareholders' equity | -$423K | $103K | $587K | $6.61M | $6.15M | $30.6M | $41.8M | $44.8M | $39.4M | $5.94M |
| Retained earnings | -$47.2M | -$46.9M | $138K | -$2.68M | -$7.03M | -$15.2M | -$23.4M | -$28.0M | -$37.8M | -$75.3M |
| Shares (wtd avg diluted) | 109M | 209M | 217M | 2.13M | 5.73M | 7.34M | 7.91M | 8.28M | 8.48M | 8.62M |
Every figure is extracted from Sanara MedTech Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.